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ABSTRACT 
 
We designed niosomes based on three lipids that differed only on the polar-head group to 
analyze the influence on the transfection efficiency. These lipids were characterized in 
terms of small-angle X-ray scattering before being incorporated into the niosomes which 
were characterized in terms of pka, size, zeta potential, morphology and physical stability. 
Nioplexes were obtained upon the addition of plasmid. Different ratios (w/w) were 
selected to analyze the influence of this parameter on size, charge and on the ability to 
condense, release and protect the DNA. In vitro transfection experiments were performed 
in HEK-293, ARPE-19 and MSC-D1 cells. Our results show that the chemical 
composition of the cationic head-group clearly affects to the physicochemical parameters 
of the niosomes and specially, to the transfection efficiency. Only niosomes based on 
cationic lipids with a dimethyl amino head group (Lipid 3) showed transfection capacity 
when compared with their counterparts amino (Lipid 1) and tripetide head-groups (Lipid 
2). Regarding cell viability, we clearly observed that nioplexes based on the cationic lipid 
3 had a more deleterious effect than their counterparts, especially in ARPE-19 cells at 
20/1 and 30/1 ratios. Similar studies could be extended to other series of cationic lipids in 
order to progress in the research of safe and efficient non-viral vectors for gene delivery 
purposes. 
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 1. INTRODUCTION 
Gene therapy has become one of the main areas of interest for scientists, because it 
focuses on the possibility of delivering a normal functioning gene into the cell in order to 
have a therapeutic effect 1. However, efficient delivery and expression of genes into cells 
is not as easy as it seems. The entry of the DNA into cells and the protection of the 
genetic material against enzymatic digestion before reaching the nucleus, are two 
important factors that may clearly hampers this process. Other factors to be considered 
for the development of effective gene carriers include the intracellular trafficking and the 
subsequent entry into the nucleus in order to express the desirable molecule.2 Basically, 
there are two main gene carrier systems classified as viral and non-viral vectors. Viral 
vectors rely on the use of viruses as carriers due to their natural ability to insert genetic 
material into the cells. However, some serious concerns such as immunogenicity, 
oncogenicity and the high cost of production jeopardize their use in human beings.3 On 
the other hand, non-viral vectors based on cationic lipids or polymers offer a safer way to 
deliver genetic material, as they exhibit lower risk of antigen-specific immune and 
inflammatory response. Moreover they are cheaper and easier to elaborate, and the size of 
DNA inserted is theoretically unlimited.4 However, non-viral vectors are less effective 
than viral vectors as gene cariers Therefore, research on the design of safe and effective 
novel non-viral vectors merits special attention for the research community.  
Niosomes are non-ionic surfactant vesicles with a bilayer structure that have been 
effectively used to vectorize many kinds of drugs.5,6 Unfortunately, these outcomes have 
not been the same for gene therapy purposes where their use is still limited; however 
some promising results have been recently reported in the literature for retinal gene 
delivery purposes.7 Therefore, research on niosomes as non-viral vectors represents a 
challenge topic to be further developed. Compared with liposomes, niosomes are 
recognized for their low cost and superior chemical and storage stabilities. The structure 
and physical properties of niosomes are similar to liposomes, with the only difference 
that niosomes are prepared using non-ionic surfactants instead of phospholipids. 
Basically, there are three main components in a niosome formulation: a) Non-ionic 
surfactants such as polysorbate 80 and span that form stable emulsions,8 b) helper lipids 
such as cholesterol or squalene that enhance the physicochemical properties of the lipid 
emulsion9,10 and c) cationic lipids, which structure and physical properties clearly 
influence on the transfection efficiency and toxicity.11 
Most of the cationic lipids employed for gene delivery purposes contain four functional 
domains: a hydrophilic head-group, a hydrophobic domain, a linker, and a backbone 
domain. The hydrophobic group is usually derived from aliphatic hydrocarbon chains. 
Classically, the hydrophobic domain often contains two linear aliphatic chains, because it 
has been reported that cationic lipids containing one or three carbon chains tend to be 
more toxic and show poor transfection efficiencies.12 The linker group influences on the 
flexibility, stability, and biodegradability of the cationic lipid, while its length determines 
the level of hydration.13 The backbone separates the polar-head group from the 
hydrophobic group, being serinol and glycerol groups the more popular units.14 
Finally, the hydrophilic head-group is responsible of the interaction with DNA and its 
condensation to form complexes due to electrostatic interactions.15. 
In the present study, we designed niosome vectors based on three synthetic amino lipids 
containing polysorbate 80 as non-ionic surfactant and squalene as helper lipid. Our three 
cationic lipids were synthesized containing the same serinol backbone with two identical 
fully hydrocarbonated alkyl chains, varying only the cationic head structure with an 
amino (Lipid 1), a tripeptide (Lipid 2) and a dimethyl amino group (Lipid 3) (Fig. 1) in 
order to study the influence of the polar-head group on the transfection efficiency and cell 
viability. The amino polar-head group (Lipid 1) was selected based on the excellent 
transfection results obtained when it was incorporated to a glycerol derivative cationic 
lipid.7 The dimethyl amino group (Lipid 3) is considered as one of the most suitable 
pendant groups for cationic lipids to be used in transfection experiments, for this reason 
was selected as a polar-head group. Finally, the tripeptide group (Lipid 2) was selected as 
polar head group as this compound has a lower pKa than dimethyl amino and amino 
groups and it may form potential intermolecular H-bonds. These novel cationic lipids 
were analyzed by small-angle X-ray scattering (SAXS). Niosomes prepared by oil-in-
water emulsion (o/w) and film-hydration technique were characterized in terms of pka, 
size, zeta potential, morphology and physical stability. Upon the addition of the 
pCMSEGFP reported plasmid, we obtained nioplexes at different cationic lipid/DNA 
ratios (w/w). The influence of cationic lipid/DNA ratios on particle size, zeta potential 
and on the ability to condense, release and protect the DNA from enzymatic digestion 
was analyzed. In vitro experiments were performed with the most promising formulations 
to evaluate the transfection efficiency and viability in HEK-293, ARPE-19 and MSC-D1 
cells. Delivery carriers prepared by biomolecular assembly and conjugation have been 
extensively reported in the literature.16-18 
 
 
2. RESULTS AND DISCUSSION 
 
2.1. Synthesis of ionizable amino lipids 
The synthesis of the three proposed ionizable amino lipids (1, 2 and 3) is displayed in Fig. 
2. The synthesis started with the double alkylation of the N-protected diol 4 in the 
presence of tetradecyl bromide and sodium hydroxide (50%) by using the transfer-phase 
catalyst reaction. This reaction afforded the alkylated compound 5 with moderate yields 
(54%). Then, N-Boc deprotection in acid conditions (CH2Cl2 / TFA 10%) and subsequent 
treatment with Amberlyte IRA-900 yielded in quantitative form the expected di-alkylated 
amine 1 (Lipid 1) in its free form. 
Further amine functionalization with an activated Boc-Gly-Gly-Gly-OH afforded the 
protected N-Boc-dialkylated tripeptide 6 with good yields. Boc-deprotection using the 
same acid conditions described before achieved the expected Lipid 2 in quantitive yield. 
Finally, a N,N-dimethylethylenediamine residue was successfully introduced into the 
Lipid 1 by activating 1 with p-nitrophenyl chloroformate. This reaction generated the 
expected Lipid 3 with good yields. (For more details see the supporting information 
section 1). 
 
2.2. Small Angle X-ray Scattering (SAXS) analysis of cationic lipids 
In Fig. 3-A, we show the SAXS curves at 25 ºC corresponding to the three amino lipids. 
No significant differences were observed at 37 ºC (data not shown). For the lipid 1 three 
equidistant peaks can be clearly observed while for lipid 2 up to 4 equidistant peaks are 
apparent. In contrast, for lipid 3 the three observed peaks are not equidistant and the 
peaks appear at positions q1: 2 q1: 4 q1. In this case the peak that should appear at 3 q1 is 
absent due to the bilayer form factor. The presence of equidistant peaks is the sign of a 
lamellar structuring of the system; therefore, we have fitted a modified Caillé Gausian 
model to the SAXS curves. In this model, the bilayer structure is calculated with two 
Gausian corresponding to the polar heads at both sides of the bilayer and one Gausian at 
the center of the bilayer corresponding to the low density methyl terminal groups of the 
hydrophobic chains. In addition, the contribution of the methylene groups of the chains is 
provided by a symmetric error function.19 The layered structure is calculated using the 
modified Caillé structure factor as found in the literature.20, 21 The electronic profiles are 
shown in Fig. 3-B, and the main parameters of the fit in Table 1 (this material is available 
in the supporting Information section 2). Lipid 1 is the one that shows a most clear 
methylene dip at the center of the bilayer, this is usually associated to strong order in the 
hydrophobic domain (the so-called gel phase found for phospholipids). The lipid 3 also 
shows a distinct low electronic density region at the center of the bilayer, albeit less 
defined than lipid 1, while the dip has completely disappeared for lipid 2. This 
corresponds to a more fluid hydrophobic domain for lipid 2. 
The other remarkable difference between the lipids is the amount of water hydrating the 
polar heads. While lipid 1 is hydrated by at most 1 water molecule and there is virtually 
no water in the liquid crystal, the liquid crystals formed by lipid 2 and lipid 3 contain 
similar amount of water, around 11 water molecules per lipid. There is, however, a 
striking difference between water location in the liquid crystal formed by lipid 2 and lipid 
3. As it can be observed in Fig. 3-B, the high electronic density of lipid 2 is distributed, 
reaching the limit of the bilayer while that of lipid 3 remains quite tightly bound to the 
hydrophobic domain of the bilayer. The meaning of this is that the polar region of lipid 3 
contains almost no water and most of the water between the bilayers is free. 
 
2.3. Determination of niosomal pKa by fluorescence 
Liposomal pKa have been used to predict the efficacy of formulations containing 
ionizable amino lipids to encapsulate and mediate delivery of different cargoes into 
cells.22 This parameter, in particular, has been used both in rational design of lipids23 and 
structure-activity relationship (SAR) studies in order to analyze combinatorial libraries of 
lipids by varying the amino cationic head group, linker or hydrophobic chains and 
thereby designing more efficient vehicles for in vivo applications. 
There are two different approaches that have been reported in order to measure amino 
lipid pKa values: 1) potentiometric titration of amino lipids prepared in niosomes and 2) 
the effect of 2-(p-toluidino)-6-naphtalene sulfonic acid (TNS) fluorescence at different 
pH.24 
In our case, the use of the second approach allowed us to determine the acid dissociation 
constant of our niosome formulations containing the ionizable amino lipids 1, 2 and 3, 
respectively by in situ TNS fluorescence titration from pH 2.5 to 11.0 (Fig. 4-A, 4-B and 
4-C). As displayed in Fig. 4, the amino lipids (1 – 3) containing the same hydrophobic 
alkyl region and serinol backbone but modifying only the cationic head group was 
sufficient to affect the pKa value for the corresponding niosomes. Therefore, the half-
maximal fluorescence intensity afforded niosomal pKa values that ranged from 6.63 to 
7.00 (lipid 1, pKa = 7.00; lipid 2, pKa = 6.63 and lipid 3, pKa = 6.72, respectively). As 
displayed in Fig. 1, lipids 1 and 2 have a primary amino group. Lipid 1 has a higher pKa 
than lipid 2. This is consistent with the presence of the electron-withdrawing amide 
groups in lipid 2 that lower the pKa. Moreover, lipid 3 is a tertiary amine with electron-
withdrawing groups and for this reason the pKa is higher than the lipid 2. It has been 
suggested that the optimal pKa of cationic lipid for transfection should be < 7.0 as in this 
way a large number of amino groups would be neutral at physiological pH 7.4.23 If this 
suggestion is correct, then the pKa of the amino lipids described in this work could fall 
the optimal range for transfection. 
 
2.4. Particle size, zeta potential and morphology evaluation of niosomes 
It has been widely reported that the uptake and transfection efficiency of non-viral 
vectors strongly depends on the method of elaboration, which clearly impact on some 
physicochemical parameters including size, zeta potential and morphology.25 Therefore, 
we prepared niosomes based on the three synthesized amino lipids by o/w emulsion and 
film-hydration techniques. Resulted niosomes were characterized in terms of size, zeta 
potential and morphology (Fig. 5). We observed that zeta potential values were similar 
between both techniques for the three niosome formulations (Fig. 5-A, lines). 
Interestingly, the highest zeta potential values were obtained when niosomes were based 
on lipid 3 (≈ +30mV), independently of the elaboration technique. Regarding particle size 
values (Fig. 5-A, bars), we did not find differences between the niosomes when these 
were elaborated by the film hydration technique (values around 200 nm). However, 
smaller particle sizes were obtained when niosomes based on the lipid 2 were formulated 
by the film-hydration technique (≈ 150 nm). In addition to the size and charge, the 
homogeneity of the suspension containing nanoparticles should be also considerate, since 
this parameter affects to the formation of the nioplexes (after the addition of plasmid) and 
the subsequent cell internalization processes.26 We determined the polydispersity index 
(PDI) as a measure of homogeneity (Fig. 5-B). Our data clearly revealed that the lowest 
PDI values were obtained when niosomes were prepared by the O/W emulsion technique, 
and these values were similar, independently of the lipid employed to formulate the 
niosomes. However, when niosomes were elaborated by the film-hydration technique, 
PDI values were extremely high, especially for niosomes elaborated with the lipids 1 and 
3 (0.9 and 1.0 values respectively), which indicates that these suspensions had a very 
broad size distribution. Therefore, the cumulative analysis to determine particle size does 
not apply to scenario. Consequently, we discarded for the following experiments the 
niosomes that were prepared using film-hydration technique. 
To get a direct evidence of the niosomes formation, we examined niosomes elaborated by 
the O/W emulsion technique with the three cationic lipids under a Cryo- TEM 
microscope (Fig. 5-C). In our experimental conditions, all niosomes, especially those 
elaborated with the lipid 3 (Fig. 5-C2) adopted a spherical and homogeneous morphology, 
which is the most favorable structure from an energetic point of view. 
In all niosome formulations, sizes reported by Cryo-TEM (around 100 nm or less) were 
slightly smaller than the sizes reported by dynamic light scattering (around 200 nm, Fig. 
5-A, bars). Such differences in the sizes of the niosomes could be explained by the 
sample manipulation required to perform Cryo-TEM analysis. 
 
2.5. Physical stability of niosomes 
Instability of niosomes can be seen as a merging of one or more particles and thus 
formation of aggregates that result in an increase on the particle size throughout the 
testing period. Therefore, the bigger is the size, the more unstable the niosomal system is. 
Normally, the electrostatic repulsions among the vesicles are due to the surface charge. 
As a rule of thumb, high surface charges of the vesicles (above 20 mV, absolute value) 
should provide enough electrostatic repulsion to prevent the formation of aggregates.10 
We measured the physical stability of niosomes based on the three cationic lipids by 
monitoring the particle size and the zeta potential after storage for 100 days at 4°C and 
25°C (Fig. 6). Our data shows that stability of niosomes strongly depended on the storage 
temperature and on the cationic lipid used to elaborate the niosomes. Clear decreases on 
the zeta potential value along the time was observed when niosomes based on lipid 1 and 
especially on lipid 2, was stored at 25°C. In the case of niosomes based on the lipid 2, the 
decrease on zeta potential led to a clear increase in the particle size, resulting in unstable 
niosomes due to the reduction of the electrostatic repulsions.27 However, zeta potential 
and size of niosomes based on the lipid 3 did no vary too much along the time when 
stored at 25°C, which clearly indicates that the polar head-group of the cationic lipid 
strongly affects to the niosome stabilities. When samples were stored in the refrigerator at 
4°C, we did not observe a clear decrease on the zeta potential value along the time, with 
the exception of niosomes based on the lipid 2 which clearly was unstable after 100 days 
of storage at 4°C. Again, a decrease in the zeta potential value led to a clear increase in 
the particle size. Temperature can lead to changes in the crystalline structure of lipids due 
to changes in zeta potential, as previously reported. 28 In conclusion, niosomes based on 
lipids 1, 2 and 3 were more stable when were stored at 4°C, specially, niosomes based on 
the lipid 3, which size and zeta potential values did not strongly vary along the 100 days 
duration of the study. 
 
2.6. Characterization of nioplexes in terms of size and zeta potential 
Adding DNA to the niosomes at different cationic lipid/DNA ratios (w/w) formed 
nioplexes that were characterized by charge and size parameters (Fig. 7). A clearer 
decrease in zeta potential value (Fig. 7, lines) was observed in the three noisome 
formulations when DNA was added at a cationic lipid/DNA mass ratio of 1/1. For 
niosomes based on the lipid 1, the charges oscillated from 18 to -35 mV, for niosomes 
based on the lipid 2, these charges oscillated from 19 to -48 mV and for niosomes based 
on the lipid 3, charges oscillated from 31 to -41 mV. Interestingly, in all nioplexes 
formulations, zeta potential values increased proportionally to the cationic lipid/DNA 
mass ratio, reaching the maximum values at the highest cationic lipid /DNA ratio 30/1 
(+8 mV, + 10mV and +22mV for nioplexes based on lipid 1, 2 and 3 respectively). This 
increase in the charge was more evident for the nioplexes prepared with the lipid 3. The 
clear relationship between the cationic lipid/DNA mass ratio and the superficial charge 
demonstrates that at an appropriate mass ratio, cationic niosomes were able to bind and 
neutralize the negative charges of the DNA, 29 resulting in positively charged nioplexes 
that can easily interact with the negatively charged cell surfaces, inducing early steps of 
the endocytosis process, which finally increases transfection efficiency.30 
Regarding the size of nioplexes (Fig. 7, bars), results in general showed that the increase 
of the cationic lipid /DNA ratios from 1:1 to 30:1 did not significantly affect to the final 
size, with some exceptions such as niosomes based on cationic lipid 1 at 25:1 and 30:1 
ratios (Fig 7-A). These slight increases in the final size could be due to the achievement 
of a final zeta potential value near to 0, which results in less compacted and bigger 
nioplexes. In general, most of the nioplexes showed a final size value under 200 nm, 
which has been report to be adequate for intracellular uptake and therefore transfection.31 
It is generally accepted that the mass ratio influences on the particle size of nioplexes.29 
However in our experimental conditions, we did not find relevant differences, probably 
because the final particle size of the resulted nioplexes may depend on a delicate balance 
between the ability of the cationic niosome to precondense with the DNA which reduces 
the particle size, and the greater space demanded by the noisome itself, which increases 
the particle size.7 
 
2.7. Agarose gel electrophoresis studies of nioplexes 
To further analyze the electrostatic interactions between the niosomes based on the three 
cationic lipids and the DNA, we performed an agarose gel electrophoresis assay, since an 
optimum balance between DNA condensation and release is mandatory to enhance 
transfection efficiency.32 Additionally, DNA can be easily degraded by enzymes in the 
cytosol before reaching the nucleus.33 Therefore, we studied the DNA protection capacity 
of niosomes based on the three cationic lipids against DNase enzymatic digestion, in 
order to design efficient non-viral carriers for gene delivery purposes. Based on the data 
obtained in Fig. 7, we selected 6/1, 10/1, 20/1 and 30/1 cationic lipid/DNA mass ratios to 
perform the agarose gel electrophoresis studies, since at cationic lipid/DNA mass ratios 
below 6/1, the zeta potential values of resulted nioplexes were negatives when nioplexes 
were formulated with lipid 1 and lipid 2. Data of agarose gel electrophoresis assays are 
shown in Fig 8. 
Nioplexes based on cationic lipid 1 (Fig. 8-A) failed to condense and therefore, to protect 
the DNA against enzymatic digestion. Clear SC bands on lanes 4, 7, 10 and 13, suggest 
that unbound DNA was able to migrate through the gel at 6/1, 10/1, 20/1 and 30/1 
cationic lipid/DNA mass ratios, respectively. As expected, DNA was easily released from 
the niosomes based on cationic lipid 1 upon the addition of SDS at all ratios studied, 
because clear SC and OC bands (in some cases comparable to control lane 2, free DNA) 
were observed on lanes 5, 8, 11 and 14. Interestingly, faint SC band observed at all mass 
ratios suggested that the DNA was partially digested upon exposition to DNases when 
niosomes were formulated with the lipid 1, which anticipates poor performance in next in 
vitro transfection experiments. 
Regarding nioplexes based on the cationic lipid 3 (Fig. 8-B), we clearly observed that the 
condensation capacity was superior to that observed when niosomes were formulated 
with lipid 1 (Fig. 8-A), since most of the DNA remained retained in the well and not clear 
SC bands were observed on lanes 4, 7, 10 and 13. Additionally, protection capacity 
increased proportionally to the cationic lipid/DNA mass ratios. Therefore, at low mass 
rations (6/1, lane 4) niosomes were no so efficient to condense DNA. When SDS was 
added, niosomes were able to release the DNA at all cationic lipid mass ratios analyzed 
(lanes 5, 8, 11 and 14), which reveals that electrostatic interactions between niosomes 
based on the lipid 3 and DNA are strong enough to condense DNA, but at the same time, 
DNA can be easily released from the niosomes upon the addition of SDS, which is an 
optimal condition for gene delivery purposes.34 Protection assays against enzymatic 
digestion revealed that niosomes based on cationic lipid 3 not only condensed and 
released the DNA, but also efficiently protected the DNA against enzymatic digestion at 
all ratios, since clear SC bands, the most bioactive form,35 were observed on lanes 6, 9, 
12 and 15. 
Nioplexes based on the cationic lipid 2 (Fig. 8-C) clearly failed to protect the DNA, as 
observed by the absence of SC or even OC bands on lanes 6, 9, 12 and 15, despite the 
fact that niosomes condensed and released properly the DNA after the addition of SDS. 
Protection capacity of DNA against enzymatic digestion is a mandatory issue that merits 
special attention for the design of efficient gene delivery vectors.36 We hypothesize that 
electrostatic interactions between the cationic lipid 2 and DNA are efficient to condense 
the DNA, but are not strong enough to protect the DNA. 
The absence of DNA bands on lane 3 (Fig 8-A, B and C) confirms that the enzyme 
worked properly in all experiments carried out. 
 
2.8. In vitro transfection experiments in HEK-293, ARPE-19, and MSC-D1 cells 
One of the main goals of non-viral gene delivery systems is to emulate transfection 
efficiencies obtained with viral vectors. Therefore, the synthesis and development of new 
safe and efficient non-viral vector carriers represents an attractive challenge for the 
scientific community that need to be overcome in order to beat gene therapy based on 
viral vectors. 
A single vector is unlikely to be optimal for all applications, since lipofection efficiency 
is a cell dependent process.37, 38 Therefore, transfection efficiency needs to be studied and 
evaluated in different cell lines, as we have presented in the current study. 
Human embryonic kidney cells (HEK-293) have been extensively used as a well-known 
and easy to transfect model.39 Human retinal pigment epithelial cells (ARPE-19) are more 
difficult to transfect cells.36 These cells are essentials for neural retina homeostasis and 
play a major role in genetic ocular diseases associated with senescence and dystrophies of 
the photoreceptors.40 Finally, mesenchymal stem cells (MSC-D1) have shown flattering 
characteristics for different medicine applications due to their capacity of differentiation 
(osteocytes, chondrocytes or adipocytes) and their ability to produce immunosuppression 
upon transplantation to name just a few. Therefore, MSC-D1 cells represent an attractive 
model for the development of safe non-viral vectors carriers despite the lack of articles 
reported on the literature.41 
Transfection results are shown on Fig. 9-A. As can be observed, only those nioplexes 
based on cationic lipid 3 showed relevant percentages of transfection. In all cases, the 
highest percentages were obtained in HEK-293, reaching 33% of transfection at the 
cationic lipid/DNA ratio 10/1. This value is clearly superior to the maximum transfection 
values obtained in both ARPE-19 (8% at 10/1 ratio) and MSC-D1 cells (1% at 20/1 ratio). 
Such differences found on transfection values among the cells could be explained by the 
different cell line dependent barriers that nucleic acids need to face before reaching the 
cellular machinery for protein synthesis, such as cellular uptake, structural changes 
caused by interactions with cellular lipids and posterior intracellular trafficking processes. 
2, 42-44
 
The lack of transfection observed when cationic lipids 1 and 2 were used to obtain 
nioplexes in the three cell lines suggests that the polar head-group of the cationic lipid 
plays a pivotal role on transfection efficiency. Therefore, minor structural changes 
performed in the cationic lipid head-groups, such as the inclusion of one additional 
methylene moiety, are able to change dramatically gene transfer efficiencies, as 
previously reported by Singh et al.45 Moreover, these differences obtained in transfection 
efficiencies with our three formulations might be hypothesized to several causes such as 
particle hydrophobicity, electrostatic interactions, lipid structures, or formation of 
aggregates between nioplexes.46, 47 
More specifically, the presence of the dimethylaminoethyl moiety as hydrophilic cationic 
head in the lipid 3 was able to impart efficiently cellular uptake of pDNA.  
Reported transfection experiments performed with other cell lines in vitro and/or in vivo 
using the same modification and other dimethylamino derivatives have shown the 
importance to maintain this cationic head into the lipid structure, probably due to the 
easiness of these amino lipids to ionize and the tendency to interact with biomembranes. 
48, 49
 Thus, niosome pKa value for niosomes based on cationic lipid 3 (pKa = 6.72, Fig. 4C) 
confirmed the correlation between activity and ionization behavior. Besides the 
dissociation effect observed for the lipid 3, the interaction between the cationic lipid and 
the DNA can influence on the transfection efficiency. In fact, this structuring promotion 
is not only due to the lipid itself, but also to the compounds that are used to prepare the 
niosomes, such as the squalene which can promote the inverted hexagonal phase by 
facilitating the lamellar to inverted hexagonal phase transition of phospholipids causing 
the endosome swelling and promote membrane fusion.50 Surprisingly, this superior 
transfection property described before for the lipid 3 was not observed for niosomes 
containing the lipids 1 and 2 which did not promote delivery of DNA in vitro even having 
similar dissociation constants (pKa = 7.00 and 6.63 for lipid 1 and 2, respectively; Fig. 4-
A, B). This lack of activity could be attributed to both molecular shape of the cationic 
lipid and the formation of closed-pack units based on electrostatic interactions and van 
der Waals’ attractions (Fig. 3-B).51 Consequently, these nioplexes might be unable to 
adopt the hexagonal morphology because of niosome packing that could become more 
stabilized and thereby inactivating the delivery process.52 As a consequence, these results 
also evidenced that pKa constant is a necessary but not sufficient condition for having a 
good DNA delivery into the cell.48 When examining other relevant physicochemical 
properties for gene deliver purposes such as size, zeta potential or morphology (Fig. 5), 
we found that niosomes based on the cationic lipid 3 were about 200 nm (Fig. 5-A, bars), 
had spherical and homogeneous morphology (Fig. 5-C2), and the zeta potential value was 
higher (around + 30 mV) than the obtained with their counterparts lipid 1 and 2 (around + 
20 mV, Fig. 5-A, lines). The higher superficial charge of niosomes based on the lipid 3 
could explain the highest stability of this formation due to electrostatic repulsion forces 
that avoid variations over the time on size and zeta potential values, as observed on Fig. 
6-B. Finally, nioplexes obtained upon the addition of DNA at different cationic 
lipid/DNA ratios (w/w), were more positively charged when the cationic lipid 3 was used 
(Fig. 7-B), which could support the data obtained in the agarose gel electrophoresis 
studies. According to this, only nioplexes formulated with the lipid 3 were able to 
condense, release and protect the DNA against enzymatic digestion at appropriate 
cationic lipid/DNA mass ratios 10/1, 20/1 and 30/1 (Fig. 8-B). All these data highlight 
that cationic lipid head groups play a relevant role on transfection efficiency, since minor 
structural changes are able to dramatically affect this process. However, not only 
transfection efficiency needs to be assessed when developing novel non-viral vector 
carriers for gene delivery purposes. The introduction of foreign DNA into the cell is not a 
natural process. Therefore, transfection is an inherent toxic process by itself. Additionally, 
cationic lipids toxicity is a highly cell dependent process that has been classically 
attributed to the induction of apoptosis and could limit the application in the clinic.53 
Results related to cell viability are summarized in Fig. 9-B. We observed a clearly cell-
dependent toxicity effect, being ARPE-19 the cells that better tolerated the nioplexes 
formulations at most ratio studied (with the exception lipid 3, ratio 30:1). Other reported 
cell viability studies performed with other niosomes based on a glycerol backbone instead 
of a serinol backbone have also shown that ARPE-19 cells tolerate the nioplexes better 
than HEK-293 cells.7 Cell-dependent toxicity effect observed could be probably due to 
differences in membrane composition as well as differences in phagocytic activity and 
processing of the nioplexes among the cells studied. 
Regarding the cytotoxic effect among our three nioplexes formulations, we clearly 
observed that nioplexes based on the cationic lipid 3 had a more deleterious effect than 
their counterparts, especially in ARPE-19 cells at 20/1 and 30/1 ratios. This toxic effect 
of nioplexes based on the cationic lipid 3 could be explained by the higher zeta potential 
of these vectors, which could destabilize cell membranes. 
To summarize, our data revealed that cationic lipid chemical structure of the hydrophilic 
group clearly influenced not only on transfection efficiency but also on cell viability. 
Therefore, the detailed study of this domain is a mandatory issue for the research 
community in order to design more efficient and safe non-viral vectors based on cationic 
lipids. 
 
3. CONCLUSION 
In the present study, we designed niosomes based on three different cationic lipids which 
differed only on the polar-head group. Our results show that the chemical composition of 
the cationic head-group clearly affects to the physicochemical parameters of the 
niosomes and specially, to the transfection efficiency. Only niosomes based on cationic 
lipids with a dimethyl amino head group (Lipid 3) showed transfection capacity when 
compared with their counterparts amino (Lipid 1) and tripeptide head-groups (Lipid 2). 
However, niosomes based on cationic lipid 3 showed a more deleterious effect than their 
counterpart lipids, especially in ARPE-19 cells at 20/1 and 30/1 ratios. Therefore, we 
hypothesize that changing the actual ether bond (linker domain) of cationic lipid 1 by a 
biodegradable ester bond could rend into better tolerated niosome formulations 
maintaining transfection efficiency, since ether bounds are too stable to be biodegraded, 
which results in higher toxicity compounds compared to ester bounds.54 In any case, 
further studies will be required to support this assumption. 
 
 
4. EXPERIMENTAL 
 
4.1. Materials 
All reagents, solvents and chemicals used in this study were of the highest purity 
available and were used as received. DNase I, sodium dodecyl sulphate (SDS), squalene 
and PBS were purchased from Sigma-Aldrich (Madrid, Spain). Polysorbate 80 (Tween 
80) was provided by Vencaser (Bilbao, Spain). All reactions were carried out under inert 
atmosphere of argon. Flash column chromatography was carried out on silica gel SDS 
0.063-0.2 mm/70-230 mesh. 1H and 13C NMR spectra were recorded at 25ºC on a Varian 
Mercury 400 MHz spectrometer using deuterated solvents. Tetramethylsilane (TMS) was 
used as an internal reference (0 ppm) for .1H spectra recorded in CDCl3 and the residual 
signal of the solvent (77.1 ppm) for 13C spectra. For CD3OD and d6-DMSO the residual 
signal of the solvent was used as a reference. Chemical shifts are reported in part per 
million (ppm), coupling constants (J) in Hz and multiplicity as follows: s (singlet), d 
(doublet), t (triplet), q (quadruplet), quint (quintuplet), m (multiplet) and br (broad signal). 
Electrospray ionization mass spectra (ESI-MS) were recorded on a Micromass ZQ 
instrument with single quadrupole detector coupled to an HPLC, and high-resolution 
(HR) ESI-MS on an Agilent 1100 LC/MS-TOF instrument (Servei d’Espectrometría de 
Masses, Universitat de Barcelona). Cell culture reagents were purchased from LGC 
Promochem (Barcelona, Spain). Opti-MEMTM I reduced medium, antibiotic/antimicotic 
solution and LipofectamineTM 2000 transfection reagents were acquired from Invitrogen 
(San Diego, California, USA). Retinal pigmented epithelial cells (ARPE-19), human 
embryonic kidney cells (HEK-293) and mouse bone marrow mesenchimal stem cells 
(MSC-D1) were obtained from the American Type Culture Collection (ATCC). 
 
4.2. Synthesis of cationic lipids 
 
4.2.1.Synthesis of tert-butyl-N-[2-tetradecyloxy-1-(tetradecyloxymethyl)ethyl]carbamate 
(5) 
Diol 4 (500 mg; 2.61 mmol) and tetradecylalkyl bromide (4.2 mL, 15.6 mmol) were 
dissolved in toluene (2.0 mL). Then, Bu4NHSO4 (444 mg; 1.305 mmol) was added along 
with a 50% solution of NaOH (3.0 mL). The mixture was heated at 60 ºC with vigorous 
stirring overnight. The reaction was diluted with AcOEt (15 mL) and the organic layer 
was washed with water (3 x 10 mL). The organic layer was dried on anhydrous MgSO4 
and solvent was evaporated obtaining the corresponding crude that was purified by flash 
chromatography (Hex 100% to Hex/AcOEt 10%). 
Yield 54%;1H -NMR (400 MHz, CDCl3) δ 4.89 (broad s, NH), 3.50 (m, 1H;CH-N), 3.41 
(m, 8H; 4 CH2-O), 1.54 (s, 9H; 3 CH3-C), 1.44(s, 9H; 3 CH3-C), 1.28 (m, 48H; alkyl 
chain), 0.88 (t, J = 6.7 Hz, 6H; 2 CH3); The spectra shows rotamers; 13C-NMR (125 MHz, 
CDCl3) δ 146.7 (CO), 85.1 (C-O), 71.3 (CH2-O), 69.1 (CH2-O), 31.8 (CH-N), 29.7, 29.6, 
29.6, 29.4, 29.3, 28.3, 27.3, 26.1, 22.6 (alkyl chain), 14.0 (CH3); ESI-MS for C36H74NO4 
m/z 584.5612 (calculated) 584.5608 (M+H)+(found); C72H146N2NaO8 m/z 1190.0971 
(calculated) 1190.0974 (2M+Na)+ (found). 
 
4.2.2. Synthesis of 1,3-di(tetradecyloxy)propan-2-amine (Lipid 1) 
N-protected alkyl diol 5 (300 mg; 0.514 mmol) was dissolved in a mixture of 
dichloromethane: trifluoroacetic acid (4:0.5; v/v). The reaction was stirred at room 
temperature for 30 minutes. The solvent was evaporated obtaining the corresponding 
amine derivative in its trifluoroacetate form. The crude was re-dissolved in AcOEt (5 
mL) and carbonate on polymer support (20 eq) was added. Mixture was stirred for 1 hour 
at room temperature. The resin was filtered off and the solvent was evaporated, obtaining 
the expected Lipid 1 which was used without further purification. 
Yield 100%; 1H -NMR (400 MHz, CDCl3) δ 3.43 (m, 6H; 3 CH2-O); 3.30 (m, 2H; CH2- 
O); 3.15 (m, 1H; CH-N); 1.26 (m, 48H; alkyl chain); 0.88 (t, J = 6.7 Hz; 6H; 2 CH3); 
13CNMR (125 MHz, CDCl3) δ 71.9 (CH2-O), 66.7 (CH2-O), 51.8 (CH2-O), 31.8 (CH-N), 
29.7, 29.6, 29.6, 29.5, 29.3, 29.3, 29.1, 25.8, 22.6 (alkyl chain), 14.0 (CH3); ESI-MS for 
C31H65NO2 m/z 484.5135 (calculated) 484.5136 (M+H)+ (found). 
 
4.2.3. Synthesis of tert-butyl-N-[2-oxo-2-[[2-oxo-2-[[2-oxo-2-[[2-tetradecyloxy-1- 
(tetradecyloxymethyl)-ethyl]amino]ethyl]amino]ethyl]amino]ethyl]carbamate (6) 
Previously, Boc-triglycine (2.0 eq) and N-hydroxysuccinimide (2.2 eq) were dissolved in 
dichloromethane (3 mL). Reaction was stirred for 5 minutes and EDC (2.4 eq) was added. 
The reaction was stirred overnight at room temperature. The organic layer was washed 
with water (3 x 5 mL) and dried over anhydrous MgSO4. The solvent was evaporated and 
crude was used in the next step without further purification. Amine alkyl diol 3 (100 mg; 
0.206 mmol) was added over the activated tripeptide. Reaction was heated at 60 ºC and 
stirred overnight. The solvent was evaporated and the resultant crude was purified by 
flash chromatography (DCM/MeOH 5%).  
Yield 86 %, 1H-NMR (400 MHz, CDCl3) δ 7.04 (broad m, NH), 6.04 (broad d, NH), 5.54 
(broad s, NH), 4.18 (broad s, NH), 3.99 (d, J = 5.7 Hz, 2H; CH2), 3.90 (d, J = 5.7 Hz, 2H; 
CH2), 3.83 (d, J = 5.7 Hz, 2H; CH2), 3.51 (m, 4H; 2 CH2-O), 3.42 (m, 5H; CH-N and 2 
CH2-O), 2.39 (t, J = 5.9 Hz, 2H), 1.54 (m, 4H; 2 CH2), 1.44 (s, 9H; 3 CH3-C); 1.26 (m, 
44H; alkyl chain), 0.88 (t, J = 7.0 Hz, 6H; 2 CH3); 13C-NMR (125 MHz, CDCl3) δ 168.5 
(CO), 166.8 (CO), 165.7 (CO), 164.7 (CO), 76.2 (C-O), 67.4 (CH2-O), 64.7 (CH2- O), 
49.7 (CH2-N), 44.9 (CH2-N), 39.0 (CH2-N), 38.9 (CH-N), 27.9 (CH3-C), 25.8, 25.7, 25.6, 
25.5, 25.3, 24.3, 22.0, 21.4, 18.7, 14.5, 13.4, 10.1, 7.8 (alkyl chain); ESI-MS for 
C42H82N4O7 m/z 755.6256 (calculated) 755.6260 (M+H)+, C42H82N4NaO7 777.6072 
(calculated) 777.6076 (M+Na)+ C84H164N8NaO14 1532.2251 (calculated) 1532.2251 
(2M+Na)+ (found). 
 
4.2.4. Synthesis of [[2-[(2-aminoacetyl)amino]acetyl]amino]-N-[2-tetradecyloxy- 
1(tetradecoxymethyl)-ethyl]-acetamide (Lipid 2) 
Boc-protected alkyl tripeptide 6 (70 mg; 0.093 mmol) was dissolved in a mixture of 10% 
trifluoroacetic acid in dichloromethane. The reaction was stirred at room temperature for 
one hour. Solvent was removed until dryness. The corresponding trifluoroacetate salt was 
dissolved in a mixture of AcOEt: MeOH (3:2) and carbonate on polymer support (20 eq) 
was added. The reaction was stirred for one hour at room temperature. The resin was 
filtered off and solvent was evaporated obtaining the corresponding Lipid 2 which was 
used without further purification. 
Yield 100%, 1H-NMR (400 MHz, CDCl3) δ 7.97 (broad s, NH), 7.14 (broad s, NH), 6.27 
(broad d, NH), 4.09 (broad s, NH2), 3.92 (m, 2H; CH2-N), 3.84 (m, 2H; CH2-N), 3.44 (m, 
2H; CH2-N), 3.34 (m, 8H; 4 CH2-O), 1.46 (m, 2H; CH2-C), 1.18 (m, 44H; alkyl chain), 
0.80 (t, J = 6.8 Hz, 6H; 2 CH3); 13C-NMR (125 MHz, CDCl3) δ 173.7 (CO), 169.3 (CO), 
168.2 (CO), 71.5 (CH2-O), 68.8 (CH2-O), 48.9 (CH2-NH2), 42.8 (CH2-N), 31.9 (CH2-N), 
29.7 (CH-N), 29.6, 29.5, 29.5, 29.4, 29.3, 26.0, 22.6 (alkyl chain), 14.0 (CH3-C); ESI-MS 
for C37H74N4O5 m/z 655.5732 (calculated) 655.5731 (M+H)+ (found). 
 
4.2.5 Synthesis of 1-(2-dimethylaminoethyl)-3-[2-tetradecyloxy-1-(tetradecoxymethyl)- 
ethyl]urea (Lipid 3) 
Previously, p-nitrophenyl-chloroformate (2.5 eq) and the di-alkylated amine 1 (50 mg; 
0.103 mmol) were dissolved in a mixture of tetrahydrofurane and dichloromethane (1:1) 
(3 mL). The reaction was cooled at 0 ºC and DIEA (2.5 eq) was carefully added dropwise. 
The solution was heated at room temperature and stirred for 4 hours. The solvent was 
removed and the resultant crude was used in the next step without further purification. 
Crude was dissolved in DMF (3 mL) and the corresponding amine derivative (1.1 eq) 
was added dropwise. The reaction was stirred overnight at room temperature. Finally, 
solvent was removed and the resultant crude was purified by flash chromatography 
(DCM: MeOH 5% to 10%) obtaining the expected Lipid 3. 
Yield 88%, 1H-NMR (400 MHz, CDCl3) δ 5.03 (broad s, NH), 4.98 (broad s, NH), 3.52 
(d, J = 4.4 Hz, 1H; CH-NH), 3.50 (d, J = 4.4 Hz, 1H; CH-NH), 3.42 (m, 8H; 4 CH2-O), 
3.25 (m, 2H; CH2-N), 2.44 (t, J = 5.9Hz, 2H; CH2-N), 2.26 (s, 6H; 2 CH3-N), 1.54 (m, 
4H; 2 CH2), 1.27 (m, 44H; alkyl chain); 0.88 (t, J = 6.7 Hz, 6H; 2 CH3); 13C-NMR (125 
MHz, CDCl3) δ 158.1 (CO), 71.3 (CH-N), 69.8 (CH2-O), 58.8 (CH2-O), 49.6 (CH2-N), 
45.0 (CH2-N), 37.8 (CH3-N), 31.9, 29.7, 29.6, 29.5, 29.3, 26.1, 22.6, 14.0 (CH3). The 
spectra shows rotamers; ESI-MS for C36H75N3O3 m/z 598.5881 (calculated) 598.5888 
(M+H)+ (found). 
 
4.3. Small Angle X-ray Scattering (SAXS) analysis of cationic lipids 
 
SAXS patterns were recorded simultaneously using a S3-MICRO (Hecus X-ray 
systems GMBH Graz. Austria) coupled to a GENIX-Fox 3D X-ray source (Xenox. 
Grenoble) which produces a detector-focused X-ray beam with λ=0.1542 nm Cu Kα-line 
at greater than 97% purity and less than 0.3% Kα. The transmitted scattering was detected 
using a PSD 50 Hecus at small-angle regime (0.09 nm-1 < q < 6 nm-1). Temperature was 
controlled through a Peltier TCCS-3 Hecus. The dry lipid samples (5 – 10 mg) were 
inserted in a glass capillary with 1mm diameter and 20 µm wall thickness (Hilgenberg, 
Germany) and HEPES buffer was added and mixed with the lípid derivatives. The 
capillaries were incubated at 25 ºC and 37 ºC for 24 h at least. The SAXS scattering 
curves were plotted as a function of the scattering vector modulus, ( )2/sin/4 θλpi=q , 
where θ is the scattering angle and λ the wavelength of the incident radiation. The system 
scattering vector was calibrated by measuring a standard silver behenate sample. 
Scattering curves were mainly smeared by the detector width because we used a detector-
focused small beam (300 x 400 µm full width at half maximum), which widens the peaks 
without a noticeable effect on peak position. The instrumentally smeared experimental 
SAXS curves were fitted to numerically smeared models for beam size and detector 
width effects. A least squares routine based on the Levenberg-Marquardt scheme was 
used. The bilayer was fitted using a three-Gaussian profile based on the MCG model.20,21 
Specifically, the bilayer is calculated as a summation of the head-groups 
contribution (in the form of a Gaussian centred at ±Zh, amplitude σh and maximum 
contrast electron density )(~
2OHHH ρρρ −= ), the methyl groups contribution (in the form 
of a Gaussian centred at 0 with amplitude σc and maximum electron density 
)(~
2OHCC ρρρ −= ). In addition to these two contributions and, as a difference with the 
original model reported by Pabst et al.,20 a third contribution corresponding to an error 
function centred at the bilayer centre and negative contrast electron density contribution 
)(~
222 OHCHCH ρρρ −=  corresponding to the difference in electron density between the 
bilayer methylene and the outer water.19 
 [ ] [ ] )(2/)(exp~2/)(exp~)(
2
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where the methylene contributions is a mirrored error function centred at the polar/non 
polar interface, 
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The unidimensional Fourier transform of the corresponding electronic profile has been 
numerically evaluated. The structure is modelled according to the modified Caillé model 
as in Pabst et al.20 (eqn (3)) and the global intensity is calculated according to equation 4, 
where Ndiff corresponds to a fraction of uncorrelated bilayers.  
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The parameters in eqn (3) correspond to N, total number of correlated bilayers, d 
repetition distance, η1 the Caillé parameter and γ to the Euler constant. 
 
4.4. Preparation of niosomes 
Niosomes based on three different synthetic cationic lipids were prepared using both the 
o/w emulsification and the film-hydration techniques. In the o/w emulsification technique, 
5 mg of the cationic lipid were gently grinded with 20 μl of squalene to obtain a fine 
powder. Then, 1 ml of dichloromethane was quickly added and emulsified with 5 ml 
aqueous phase containing non-ionic surfactant polysorbate 80 (0.5%, w/w). The emulsion 
was obtained by sonication (Branson Sonifier 250, Danbury) during 60 s at 50 W in ice 
bath. The organic solvent was removed from the emulsion by evaporation under magnetic 
agitation for 4 h. Upon dichloromethane evaporation, a dispersion containing the 
nanoparticles was formed by precipitation of the cationic nanoparticles in the aqueous 
medium. In the Film-Hydration technique, 5 mg of the cationic lipid were gently grinded 
with 20 μl of squalene to obtain a fine powder. Then, 1 ml of dichloromethane was added 
and thoroughly mixed to obtain the organic phase. Then, the solvent was evaporated 
under magnetic agitation for 4 h. Under DCM evaporation, the lipid film obtained was 
hydrated with 5 ml aqueous phase containing non-ionic surfactant polysorbate 80 (0.5%, 
w/w). The emulsion was obtained by sonication (Branson Sonifier 250, Danbury) during 
60 s at 50 W in ice bath. We obtained the same niosome concentration using both 
techniques (1mg cationic lipid/ml). 
 
4.5. Plasmid propagation and preparation of nioplexes 
pCMS-EGFP plasmid was propagated in Escherichia coli DH5-α and purified using the 
Qiagen endotoxin-free plasmid purification Maxi-prep kit (Qiagen, Santa Clarita, CA, 
USA) according to the manufacturer’s instructions. Concentration of pDNA was 
quantified by measuring absorbance at 260 nm using a NanoDrop® (ND-1000 
Spectrophotometer, Thermo Fisher Scientific Inc. Denver, USA). The purity of the 
plasmid was verified by agarose gel electrophoresis in Tris Borate-EDTA buffer, pH 8.0 
(TBE buffer). DNA bands were detected using GelRed™ (Biotium, Hayward, California, 
USA) to stain DNA and images were observed with a ChemiDoc™ MP Imaging System 
(Bio-Rad, USA). 
The nioplexes (Niosome/DNA vectors) were elaborated by mixing an appropriate volume 
of a stock solution of pCMS-EGFP plasmid (0.5 mg/ml) with different volumes of the 
niosome suspensions (1mg cationic lipid/ml). The mixture was left for 30 min at room 
temperature to enhance electrostatic interaction between the cationic lipids of the 
niosomes and the negatively charged plasmid. The Niosome/DNA ratio was referred as 
the ratio of cationic lipid to DNA (w/w). The stock solutions of cationic lipid (1 mg/ml) 
corresponds to the following molar concentrations : 2.07 mM (Lipid 1, MW 484), 1.53 
mM (Lipid 2, MW 655), and 1.67 mM (Lipid 3, MW 598). The stock solution of plasmid 
pCMS-EGFP of 0.5 mg/ml was estimated to be around 0.137 micromolar (pCMS-EGFP, 
5541 bp, average MW 3657060). 
 
4.6. TNS fluorescence titration assay for the determination of the pka value of the 
niosomes 
Fluorescent measures were recorded on a SpectraMax M5 spectrophotometer (Molecular 
Devices) with the excitation wavelength (λex) set at 321 nm and the emission wavelength 
(λem) set at 445 nm. Niosomes were diluted to 75 µM cationic lipids (1, 2 and 3) in 100 
µL of buffer solutions containing 10 mM HEPES, 10 mM MES, 10 mM ammonium 
acetate and 150 mM NaCl with pH ranging between 2.5 and 11.1. A stock solution of 
TNS dissolved in DMSO was added to the above buffer solution to obtain a 1 µM TNS 
solution. Solutions were mixed thoroughly and the resultant fluorescence was measured 
at room temperature. Fluorescence values are results from triplicate measurements. The 
fluorescence of TNS (normalized) was plotted against pH. Curves were fitted using a 
sigmoid function. The pka values of the cationic lipids were calculated as the pH values at 
which TNS fluorescence is half-maximal fluorescence intensity. 
 
4.7. Size and zeta potential measurements 
The hydrodynamic diameter of the niosomes and nioplexes were determined by Dynamic 
Light Scattering (DLS) using a Zetasizer Nano ZS (Malvern Instrument, UK). Briefly, 50 
µl of the niosomes or nioplexes were resuspended into 950 µl of 0.1 mM NaCl solution 
to determined size and PDI. All measurements were carried out in triplicate. The particle 
size reported as hydrodynamic diameter was obtained by cumulative analysis. 
The zeta potential was obtained by Lasser Doppler Velocimetry (LDV) using a Zetasizer 
Nano ZS (Malvern Instrument, UK). Samples were resuspended (50 µl) into 0.1 mM 
NaCl (950 µl) using folded capillary cells for zeta analysis. The Smoluchowski 
approximation was used to support the calculation of the zeta potential from the 
electrophoretic mobility. Zeta potential measurements were run in triplicate. Only data 
that met the quality criteria according with the software program (DTS 5.0) were 
included in the study. 
 
4.8. Cryo-TEM microscopy of niosomes 
The morphology of niosomes was observed by Cryo-TEM microscopy. Briefly, one drop 
of the sample solution was vitrified by rapid freezing in liquid ethane using a Vitrobot 
Markt IV (FEI). This vitrified sample grid was transferred through 655 Turbo Pumping 
Station (Gatan) to a 626 DH Single Tilt Liquid Nitrogen Cryo-holder (Gatan), where was 
maintained about -180ºC. Copper grid (300 mesh Quantifoils) was hydrophilized by 
glow-discharge treatment. The sample was examined in a TEM, TECNAI G2 20 TWIN 
(FEI), operating at an accelerating voltage of 200 KeV in a bright-field and low-dose 
image mode. 
 
4.9. Physical stability study of niosomes 
The physical stability of niosomes based on three different synthetic cationic lipids was 
determined by monitoring the particle size and zeta potential after storage for 100 days at 
4°C and 25°C. All samples were measure in triplicate. 
 
4.10. Agarose gel electrophoresis studies of nioplexes 
Naked DNA or nioplexes at different ratios (20 µl, containing 200 ng of the plasmid) 
were subjected to electrophoresis on an agarose gel (0.8%). The gel was immersed in a 
tris-acetate-EDTA buffer and exposed for 30 min to 120 V. DNA bands were stained 
with GelRed™ (Biotium, Hayward, California, USA) and images were observed with a 
TFX-20M transilluminator (Vilber-Lourmat, Germany). To analyze the release of DNA 
from the formulation, 12 µl of a 7% SDS solution was added to the samples to get a final 
SDS concentration of 3.5% in each well. The pDNA protection capacity of the vectors 
against enzymatic digestion was analyzed by adding the DNase I enzyme to the vector 
formulations (final concentration of 1 U DNase I/2.5 µg DNA). 
Afterwards, the mixtures were incubated at 37° C for 30 min and finally, 12 µl of a 7% 
SDS solution was added to analyze the released DNA. The integrity of the DNA in each 
sample was compared to a control of untreated DNA. 
 
4.11. Cell culture and in vitro transfection protocols 
HEK-293, ARPE-19 and MSC-D1 cells were seeded in 24 well plates at an initial density 
of 15 x 104, 10 x 104, and 8 x 104 cells/well, with 300 µl of EMEM containing 10% horse 
serum, 300 µl of D-MEM/F-12 containing 10% bovine serum, and 300 µl of DEMEM 
containing 10% horse serum, respectively. Cells were adhered overnight to reach 70-90% 
of confluence at the time of transfection. Then, the regular growth medium was removed 
and the cells were exposed to nioplexes resuspended in Opti-MEM® transfection medium 
at different cationic lipid/DNA ratios, containing all of them 1.25 µg of the plasmid. Each 
formulation was used in triplicate. After 4 h of incubation at 37ºC, the nioplexes were 
replaced by 500 µl of regular growth medium. Cells were allowed to grow for 72 h until 
flow cytometry analysis. Following the manufacturer’s protocol, lipofectamineTM 2000 
was used in combination with pDNA, as transfection positive control. 
 
4.12. Transfection efficiency and cell viability measurement 
Flow cytometry analysis was conducted using a FACSCalibur system flow cytometer 
(Becton Dickinson Bioscience, San Jose, USA) in order to quantify the % of EGFP 
positive cells. Cells were washed twice in PBS and detached from the microplate with 
200 µl of trypsin/EDTA and 400 µl of normal growth medium were added. The pellets 
were resuspended in growth medium, diluted in FACSFlow liquid and directly introduce 
to the flow cytometer. Transfection efficiency was expressed as the percentage of EGFP 
positive cells at 525 nm (FL1). Control samples (non-transfected cells) were displayed on 
a forward scatter (FCS) versus side scatter (SSC), dot plot to establish a collection gate 
and exclude cell debris. Other examples containing Lipofectamine transfected cells, and 
non-transfected cells were used as controls to compensate FL2 signal in FL1 channels. For 
each sample 10,000 events were collected. 
Cell viability of the three cell lines was evaluated using the Cell Counting Kit-8 (CCK-8; 
Dojingo Molecular Technologies, Inc, Gaithersburg, MD) according with the 
manufacturer´s protocol. Briefly, cells were exposed to nioplexes under the same 
conditions as described before. 72 h later, 10 µl of CCK-8 solution was added to 200 µl 
of medium in each well, and the plate was incubated 4 h at 37°C and 5% CO2. Relative 
cell viability percentage (%) was calculated based on the absorbance (Infinite M200 
microplate reader, Tecan GENios, Switzerland) observed at 450 nm. Each formulation 
was used in triplicate. 
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FIGURES 
 
 
Figure 1. General structure for the novel amino lipid-based serinol derivatives (lipids 1, 2 
and 3) containing the same backbone, hydrophobic part and several cationic heads. 
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Reagents and Conditions  a. Alkyl bromide (C14H29Br), Bu4NHSO4, NaOH 50%, Toluene, 60 ºC, overnight; b. i. DCM:TFA 10%, 
r.t., 30 min; ii. carbonate resin, AcOEt, r.t., 1h; c. i. p-nitrophenyl-chloroformate, DIEA, THF:DCM, r.t., 4h; ii. 2-dimethylaminethyleneamine, 
DMF, r.t., overnight; d. i. 3GlyBoc-OH, NHS, EDC, DCM, r.t., overnight; ii. DCM:TFA 10%, 30 min, r.t., iii. 6, carbonate resin,
AcOEt:MeOH (1:5), r.t., 1h. 
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Figure 2. Synthetic strategy for the synthesis of the ionizable lipids 1, 2 and 3. 
 
  
 
 
Figure 3. A) Scattered intensity at 25 ºC of the lipids after incubation with HEPES buffer. The lines 
correspond to the best fit of correlated lamellae, see text for the details. The curves have been scaled 
by factors of 10, the original scale corresponds to lipid 3. B). Electron density contrast relative to water 
perpendicular to the bilayer for lipid 1 (full line, upper-down arrow), Lipid 2 (dashed line, down arrow) 
and lipid 3 (dotted line, up arrow) as obtained from the fits of the scattering curves of figure A. The 
arrows mark the limit of the corresponding layer. 
 
 
 
 
 
Figure 4. In situ TNS fluorescence titration to determining the pka of niosomes bases on three cationic 
lipids. A) Sigmoidal curve showing TNS fluorescence as a function of pH in the presence of lipid 1 (75 
μM), TNS (1 μM) and buffer solution (total volume 100 μL), B) Sigmoidal curve showing TNS 
fluorescence as a function of pH in the presence of lipid 2 (75 μM), TNS (1 μM) and buffer solution 
(total volume 100 μL), C) Sigmoidal curve showing TNS fluorescence as a function of pH in the 
presence of lipid 3 (75 μM), TNS (1 μM) and buffer solution (total volume 100 μL).  
 
 
 
Figure. 5. Physicochemical characterization of niosomes based on lipids 1, 3 and 2. A) Size (dotted 
and hatched bars, which correspond to niosomes synthesized by film-hydration and o/w emulsion 
techniques respectively) and Zeta potential values (dotted and continuous lines which correspond to 
niosomes synthesized by film-hydration and o/w emulsion techniques respectively). B) PDI values. 
Each value represents the mean ± standard deviation of three measurements. C) Cryo-TEM images of 
niosomes prepared by the o/w emulsion technique. Niosomes were based on lipid 1 (C1), lipid 3 (C2) 
and lipid 2 (C3). Scale bar = 100 nm. 
 
  
 
Figure 6. Physical stability of niosomes based on lipid 1 (A), lipid 3 (B) and lipid 2 (C), following 
storage at 4°C and 25°C for 100 days. Dark and white bars correspond to particle sizes obtained at 
4°C and 25°C respectively, while continuous and dotted lines correspond to zeta values obtained at 
4°C and 25°C. A) lipid 1, B) lipid 3 and C) lipid 2. Each value represents the mean ± standard deviation 
(SD) from three independent experiments. 
 
  
Figure. 7. The influence of the cationic lipid/DNA ratio (w/w) on the particle size (bars) and zeta 
potential (lines) of niosomes based on: A) lipid 1, B) lipid 3 and C) lipid 2. Each value represents the 
mean ± standard deviation of three measurements. 
  
Figure 8. Binding, protection, and SDS-induced release of DNA from niosomes at different cationic 
lipid/DNA ratios (w/w) visualized by agarose electrophoresis. OC: open circular form, SC: supercoiled 
form. Lanes 1-3 correspond to free DNA; lanes 4-6, cationic lipid/DNA ratio 6/1; lanes 7-9, cationic 
lipid/DNA ratio 10/1; lanes 10-12, cationic lipid/DNA ratio 20/1; lanes 13-15, cationic lipid/DNA ratio 
30/1. Nioplexes were treated with SDS (lanes 2,5,8,11 and 14) and DNase I + SDS (lanes 3,6,9,12 
and 15). A) Nioplexes based on cationic lipid 1, B) Nioplexes based on cationic lipid 3, C) Nioplexes 
based on cationic lipid 2. 
  
 
Figure 9. In vitro transfection experiments of nioplexes based on cationic lipids 1, 3 and 2 in HEK-293, 
ARPE-19 and MSC-D1 cells. A) Transfection efficiency at different cationic lipid/DNA ratios (w/w). B) 
Cell viability at different cationic lipid/DNA ratio (w/w). 
 SUPPLEMENTARY MATERIAL. 
 
In situ TNS fluorescence tritation to determining pka of cationic lipids (1, 2 and 3) 
Sigmoidal curve showing TNS fluorescence as a function of pH in the presence of amino 
lipid 1 (75 µM), TNS (1 µM) and buffer solution (total volume 100 µL) 
 
 
Sigmoidal curve showing TNS fluorescence as a function of pH in the presence of amino 
lipid 2 (75 µM), TNS (1 µM) and buffer solution (total volume 100 µL) 
 
 Sigmoidal curve showing TNS fluorescence as a function of pH in the presence of amino 
lipid 3 (75 µM), TNS (1 µM) and buffer solution (total volume 100 µL) 
 
 tert-butyl-N-[2-tetradecoxy-1-(tetradecoxymethyl)ethyl]carbamate (2) 
 
 
ppm (f1)
0.05.010.0
 
 
ppm (f1)
050100150
 
 1,3-di(tetradecoxy)propan-2-amine (3) 
 
 
ppm (t1)
0.05.010.0
 
 
ppm (f1)
050100150
 
 1-(2-dimethylaminoethyl)-3-[2-tetradecoxy-1-(tetradecoxymethyl)ethyl]urea (4) 
 
 
ppm (f1)
0.05.010.0
 
 
ppm (t1)
050100150
 
 tert-butyl-N-[2-oxo-2-[[2-oxo-2-[[2-oxo-2-[[2-tetradecoxy-1-(tetradecoxymethyl)-
ethyl]amino]ethyl]amino]ethyl]amino]ethyl]carbamate (5) 
 
 
ppm (t1)
0.05.010.0
 
 
ppm (f1)
050100150
 
 
 2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-N-[2-tetradecoxy-1-
(tetradecoxymethyl)ethyl]-acetamide (6) 
 
 
ppm (f1)
0.05.010.0
 
 
ppm (f1)
050100150
 
 Table S1. Main parameters of the fits corresponding to the Figure 3B 
 
 Lipid 1 Lipid 2 Lipid 3 
reduced χ2 50 65 6 
d (nm) 4.08 5.47 5.41 
η 0.0176 0.03758 0.00882 
N 68 100 111 
σH (nm) 0.22 0.37 0.12 
ρH (e/nm3) 182 126 178 
ZH (nm) 1.98 1.98 1.91 
σH (nm) 0.13 1.02 0.31 
ZCH2 (nm) 1.75 1.60 1.89 
Am (nm2) 0.46 0.45 0.46 
Nw 1 6 1 
Nw* 0 0 5 
d repetition distance, η Caillé parameter, N number of correlated bilayers, σH 
width of  the polar head Gaussian, ρH electron density relative to the water 
medium, ZH position of the polar head Gaussian, σH width of the methyl Gaussian, 
ZCH2 width of the methylene error function, Am area per lipid molecule, Nw bound 
water molecules, Nw* free water molecules. 
 
 
 
